Has Puneet Sayal, MD received payments from drug or device companies?

Yes. Drug and device makers reported $152,699 in general payments to Puneet Sayal, MD across 343 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Puneet Sayal, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Puneet Sayal, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Puneet Sayal, MD

Pain Medicine · Corpus Christi, TXNPI 1851655914

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $100,782 of the $152,699 with a category attached, or 66.0%. SPR Therapeutics, Inc accounts for 95.5% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2023 at $90,230 and has fallen 99.9% since, to $102 in 2025. Among pain medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$152,699in general payments, 2019–2025

Across 343 payments — averaging $445.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

SPR Therapeutics, Inc$146K
Nalu Medical, Inc.$1K
Boston Scientific$1K
Nevro Corp.$1K
Abbott$797
Medtronic$707
plus $2K from 23 others

$106in research payments, 2019–2025

Across 1 payment — averaging $106.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Saluda Medical Americas, Inc.$106

What the payments were for

Consulting fees$100,78266%
Travel & lodging$38,89325%
Food & beverage$13,0249%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
SPR Therapeutics, Inc	128	$145,823
Nalu Medical, Inc.	15	$1,252
Boston Scientific	46	$1,216
Nevro Corp.	26	$1,178
Abbott	39	$797
Medtronic(2 entities)	25	$707
Avanos Medical	7	$262
Relievant Medsystems, Inc.	4	$210
Saluda Medical Americas, Inc.	3	$189
Vertiflex, Inc.	2	$132
AbbVie(2 entities)	7	$114
Stimwave Technologies Incorporated	2	$111
Collegium Pharmaceutical, Inc.	6	$91
Lilly USA, LLC	5	$85
Tersera Therapeutics LLC	4	$77
Biodelivery Sciences International, Inc.	5	$76
Arbor Pharmaceuticals, Inc.	4	$61
Upsher-smith Laboratories LLC	2	$43
Vertical Pharmaceuticals, LLC	2	$39
Merz Pharmaceuticals, LLC	1	$34
Pfizer	2	$33
Biohaven Pharmaceuticals, Inc.	1	$27
Amgen	1	$23
Pacira Pharmaceuticals Incorporated	1	$21
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$21
Scilex Pharmaceuticals Inc.	1	$21
Teva Pharmaceuticals USA, Inc.	1	$20
Bioventus LLC	1	$19
Kowa Pharmaceuticals America, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$152,699 in reported general payments places this provider in the 95th percentile of 583 pain medicine providers in Texas.

See all pain medicine providers in Texas →

Medicare billing

Part B allowed, 2024

$11,337

Medicare patients

Services billed

113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gabapentin	92	$1,253
Tizanidine Hcl	32	$527
Pregabalin	27	$521
Cyclobenzaprine Hcl	26	$353

Paid to pharmacies, not to this prescriber.

Other pain medicine in Corpus Christi

Melissa MurphyGrapevine$653K
Shiraz YazdaniLubbock$514K
Aaron CalodneyTyler$296K
Candice BurnetteSugar Land$265K
Ashley Bailey-ClassenFort Worth$244K
Grant ChenHouston$175K
Gunjan PatelHouston$166K
Anthony BergRockwall$165K
Eduardo GarciaWebster$147K
Jaideep MehtaHouston$134K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →